Revenue Diagnostics for Founder-Led B2B

Your Revenue System Is Leaking

Elevare finds and fixes the structural breakdowns between lead creation and closed won. Fixed-scope diagnostics. Hands-on implementation.

$2B+
Revenue cycles managed
15 yrs
Sales leadership
60 days
To measurable results
Where Revenue Gets Lost
Lead Creation 100%
Slow routing · Bad lead quality
Qualification 62%
Broken handoff · Weak criteria
Proposal / Estimate 38%
Stalled deals · No follow-through
Negotiation 21%
Forecast drift · Poor visibility
Closed Won 12%

These aren't strategy failures. They're structural breakdowns.

Pipeline looks full but revenue is unpredictable

Deals are in the CRM. Numbers look right. But closed-won keeps missing forecast.

Deals stall in the middle of the funnel

Discovery goes well. Proposals go out. Then silence — deals sit in the same stage for weeks.

Forecasts miss consistently

Leadership adjusts on gut feel. Nobody trusts the data. The board starts asking harder questions.

The founder is still the best salesperson

You hired reps. They're working. But close rate never matches yours — and nobody can explain why.

If this sounds familiar, it's structural. The Revenue Autopsy finds exactly where.

Start Here

Two lanes. One core problem.

SaaS & Tech-Enabled Services

$1M–$10M revenue · 10–50 employees · 1–8 reps

Pipeline looks full but conversion is weak
Outbound runs but meetings don't convert
First sales hires are underperforming
Founder's sales motion didn't transfer to the team
Forecast misses keep happening

Industrial, Commercial & Field Services

$3M–$25M revenue · 15–150 employees · Midwest and beyond

Leads come in but follow-up is inconsistent
Quote-to-close conversion is weak
Sales and ops are disconnected
Owner is still the best closer
Forecasting is gut feel with no clean visibility

Diagnose first. Implement second.

Start Here

Revenue Autopsy

Fixed-scope diagnostic. We audit your revenue system, surface the highest-leverage breakdowns, and deliver a prioritized fix plan. 4 weeks. Fixed fee.

Book a Revenue Autopsy
After the Autopsy

Revenue Rebuild Sprint

Hands-on fix of the top 1–3 breakdowns from the Autopsy. Pipeline redesign, CRM cleanup, forecasting models, workflow automation. 60–90 days.

Ongoing

Revenue Advisory

Ongoing deal review, pipeline accountability, and quarterly system health checks for founders and revenue leaders.

Clear scope. Fixed timeline. No open-ended consulting.

Audit
Week 1

Revenue System Mapping

Pipeline data, CRM structure, deal stages, handoffs, and conversion metrics.

Diagnose
Week 2

Deal Progression Analysis

Active deals, stall patterns, qualification logic. Interviews with leadership and key reps.

Architect
Week 3

Breakdown Identification

Structural breakdowns in conversion, handoffs, forecasting, and execution.

Execute
Week 4

Readout & Fix Plan

Live readout with your leadership team. Prioritized findings and a concrete fix plan.

What changes when the revenue system actually works.

Composites from real engagements. Anonymized. Actual results.

Series B SaaS
41%
"We cut our sales cycle nearly in half once the handoff process was rebuilt."
VP Sales, Series B SaaS
Growth-Stage Tech Services
3.2x
"Pipeline conversion went from noise to signal in under 60 days."
CEO, Tech-Enabled Services
Industrial Services
90%+
"For the first time, our forecast actually meant something to the board."
COO, Industrial Services

"The most valuable thing wasn't the framework. It was finally being able to tell the board what was actually in the pipeline — and have that number mean something."

VP Sales, Series B SaaS

Josh DeLucia, Founder of Elevare
15+ years Enterprise Revenue Leadership

Built by someone who ran revenue — not consulted on it.

15+ years leading enterprise sales organizations. Quota-carrying teams. Forecasting rebuilds. Founder coaching. Josh left the inside to fix the same breakdowns from the outside.

No agency. No associate team. No junior analysts. Josh works directly with your leadership team.

Learn More About Josh

Most companies are surprised by what the Autopsy surfaces.

Not because the problems are exotic — because nobody had looked at the full system before.